BB's Stock Haven

[Penny Stocks 2.0]

ENUM .0068 MERCK: collaboration with a leading immuno-oncology pharmaceutical company
– Focused on using Enumeral's platform to interrogate the tumor microenvironment in colorectal cancer
tissues to identify functional cellular responses to therapies being developed by Merck
– R&D funding and undisclosed milestone payments
– Merck has exclusive rights to data related to its proprietary compounds
– ENUM has achieved first milestone in the collaboration
– Expanded scope of work to include non-small cell lung cancer
• NCI: awarded Phase 2 contract in September 2014 for ~$1 million over two years
– Automation of human tissue immuno-oncology profiling
– Opens door to broader pipeline and potentially accelerated development
– Collaboration with leading scientists:
– Jedd Wolchok’s group at MSKCC - genetic basis for response to checkpoint inhibitors and novel immunotherapeutics
– Doug Kwon’s group at MGH/Ragon Institute - pioneering techniques for single cell immune cell analysis in biopsy